Seong Hyo Jin, Kim Yong Joon, Choi Eun Young, Lee Junwon, Byeon Suk Ho, Kim Sung Soo, Koh Hyoung Jun, Lee Sung Chul, Lee Christopher Seungkyu
Department of Ophthalmology, Institute of Vision Research, Severance Hospital, Yonsei University College of Medicine, 50-1, Yonseiro, Seodaemun-gu, Seoul, Republic of Korea.
Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Republic of Korea.
Graefes Arch Clin Exp Ophthalmol. 2022 May;260(5):1713-1721. doi: 10.1007/s00417-021-05487-4. Epub 2021 Nov 11.
This study aims to report complications, treatments, and visual prognosis of choroidal osteoma.
We retrospectively reviewed electronic medical records and multimodal images of 41 patients with choroidal osteoma.
Visually significant complications included choroidal neovascularization (CNV) in 21 (47.7%) eyes and subretinal fluid (SRF) without CNV in 14 (31.8%) eyes. The most common treatment was intravitreal anti-vascular endothelial growth factor (VEGF) injection: 13 (61.9%) eyes with CNV received an average of 6.3 injections, and 6 (42.9%) eyes with SRF but without CNV received 1.8 injections. As the first-line treatment, intravitreal anti-VEGF injection induced complete or partial remission in 93.4% of eyes with CNV and 57.1% of eyes with SRF. The probability of legally low vision estimated at 3 and at 5 years was 29.1% and 34.2%, respectively. The presence of CNV and outer retinal tubulation (ORT) was independent risk factors for vision loss (adjusted odds ratio, 8.08 and 6.94, respectively).
The development of CNV and ORT was strong risk factors for visual impairment. Due to the frequent recurrence of complications and poor visual prognosis, regular check-ups and appropriate treatment choices are warranted.
本研究旨在报告脉络膜骨瘤的并发症、治疗方法及视力预后情况。
我们回顾性分析了41例脉络膜骨瘤患者的电子病历和多模态影像资料。
具有明显视力影响的并发症包括21只眼（47.7%）出现脉络膜新生血管（CNV），14只眼（31.8%）出现无CNV的视网膜下液（SRF）。最常用的治疗方法是玻璃体内注射抗血管内皮生长因子（VEGF）：13只（61.9%）有CNV的眼睛平均接受了6.3次注射，6只（42.9%）有SRF但无CNV的眼睛接受了1.8次注射。作为一线治疗，玻璃体内注射抗VEGF使93.4%有CNV的眼睛和57.1%有SRF的眼睛实现了完全或部分缓解。3年和5年时法定低视力的估计概率分别为29.1%和34.2%。CNV和视网膜外层管状化（ORT）的存在是视力丧失的独立危险因素（调整后的优势比分别为8.08和6.94）。
CNV和ORT的发生是视力损害的强烈危险因素。由于并发症频繁复发且视力预后不佳，有必要进行定期检查并选择合适的治疗方法。
